MAPT and Alzheimer disease: Whereas Dani et al. showed that [11C]PBR28-measured microglial activation correlates with both tau and Aβ deposition assessed by [18F]flortaucipir and [18F]flutemetamol in patients with AD (69) (Figures 2D, E).